For the twelve months ended Sep 30, 2026, UroGen Pharma Ltd. reported $250.25M of revenue and -$65.75M of net income.
URGN revenueQ3 2026$89.00M
- Quarter YoY
- +223.9%
- QoQ
- +22.8%
- FY YoY
- +21.4%
- 5Y CAGR
- +56.2%
URGN revenue was $89.00M in fiscal Q3 2026 (ended Sep 30, 2026), up 223.9% from a year earlier and up 22.8% from the prior quarter. For the full fiscal 2025 it was $109.79M, up 21.4% from fiscal 2024. Compound annual growth was +56.2% over 5 years. It rose in 6 of the last 9 fiscal years. Fiscal 2025 is the highest of the 10 fiscal years on file.
URGN net incomeQ3 2026-$1.46M
URGN net income was -$1.46M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$33.35M a year earlier. For the full fiscal 2025 it was -$153.49M, compared with -$126.87M in fiscal 2024.
URGN free cash flowQ3 2026-$15.27M
URGN free cash flow was -$15.27M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$42.36M a year earlier. For the full fiscal 2025 it was -$162.73M, compared with -$97.06M in fiscal 2024.
Source: XBRL data UroGen Pharma Ltd. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.